X0508 4 2024-02-27 0 0001763950 Lantern Pharma Inc. LTRN 0001813316 Kreis Leslie W. C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX 75201 0 0 1 0 0001813270 Cavu Management, LP C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX 75201 0 0 1 0 0001813310 Cavu Advisors, LLC C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX 75201 0 0 1 0 0001813311 BP Directors, LP C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX 75201 0 0 1 0 0 Common Stock 217553 I By Bios Fund I QP, LP Common Stock 371950 I By Bios Fund I, LP Common Stock 2024-02-27 4 S 0 4649 4.40 D 68997 I By Bios Fund II NT, LP Common Stock 2024-02-28 4 S 0 6909 4.85 D 62088 I By Bios Fund II NT, LP Common Stock 2024-02-29 4 S 0 1832 4.87 D 60256 I By Bios Fund II NT, LP Common Stock 2024-02-27 4 S 0 34731 4.40 D 515412 I By Bios Fund II QP, LP Common Stock 2024-02-28 4 S 0 51608 4.85 D 463804 I By Bios Fund II QP, LP Common Stock 2024-02-29 4 S 0 13686 4.87 D 450118 I By Bios Fund II QP, LP Common Stock 2024-02-27 4 S 0 10620 4.40 D 157797 I By Bios Fund II, LP Common Stock 2024-02-28 4 S 0 15780 4.85 D 142017 I By Bios Fund II, LP Common Stock 2024-02-29 4 S 0 4185 4.87 D 137832 I By Bios Fund II, LP Common Stock 26093 I By BP Directors, LP The price reported in Column 4 is a weighted average price. On February 27, 2024 each of Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $4.35 to $4.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (3) to this Form 4. The price reported in Column 4 is a weighted average price. On February 28, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.60 to $5.21, inclusive. The price reported in Column 4 is a weighted average price. On February 29, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.62 to $5.33, inclusive. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Aaron Glenn Louis Fletcher as the designated filer. Leslie W. Kreis, Jr By: /s/ Daniel Schwarz, as attorney-in-fact 2024-02-29 Cavu Management, LP By: Cavu Advisors, LLC, its general partner By: /s/ Daniel Schwarz, as attorney-in-fact 2024-02-29 Cavu Advisors, LLC By: /s/ Daniel Schwarz, as attorney-in-fact 2024-02-29 BP Directors, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP By: Cavu Advisors, LLC, its general partner By: /s/ Daniel Schwarz, as attorney-in-fact 2024-02-29